Search Results for: NeuroSense

ALS treatment slows progression

A 12-months Phase 2b trial of PrimeC from Israel’s NeuroSense (see here previously) showed a 73% improvement over placebo in slowing ALS progression among patients. It also achieved a 63% increase in survival rates. https://finance.yahoo.com/news/neurosenses-paradigm-als-clinical-trial-132700722.html  

Posted in Israel's Medical Achievements | Leave a comment

Startups partner to detect ALS

Israel’s NeuraLight (see here) and NeuroSense Therapeutics (see here) are partnering to improve the diagnosis and monitoring of Amyotrophic lateral sclerosis (ALS). They will study patients using NeuroSense’s biological markers, together with Neuralight’s digital oculometric biomarkers. https://www.calcalistech.com/ctechnews/article/rj06yaktc

Posted in Israel's Medical Achievements | Leave a comment

Double boost for potential ALS treatment

The US FDA has given Orphan drug status to the PrimeC ALS therapy from Israel’s NeuroSense (see here). Meanwhile, NeuroSense has begun Phase 1 human clinical trials of PrimeC at two US sites and a Phase 2a human trial at … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Over one thousand backers for ALS therapy developer

I reported previously (Mar 2017) on Israel’s NeuroSense, which is developing a treatment for amyotrophic lateral sclerosis (ALS). NeuroSense has just raised NIS 4 million from over 1,100 backers in a crowdfunding campaign. https://www.calcalistech.com/ctech/articles/0,7340,L-3767719,00.html

Posted in Economy & Business | Leave a comment

New treatment for ALS

Israel’s NeuroSense Therapeutics is developing a treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. It is based on a discovery by Weizmann Institute Professor Eran Hornstein of a micro-RNA molecule lacking in the muscles of ALS … Continue reading

Posted in Israel's Medical Achievements | Leave a comment